Zacks Investment Research Downgrades Theseus Pharmaceuticals (NASDAQ:THRX) to Sell

Theseus Pharmaceuticals (NASDAQ:THRX – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Wednesday, Zacks.com reports.

According to Zacks, “Theseus Pharmaceuticals Inc. is a biopharmaceutical company. It focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company’s principal product candidate includes THE-630. Theseus Pharmaceuticals Inc. is based in CAMBRIDGE, Mass. “

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Theseus Pharmaceuticals in a research report on Friday, April 1st. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $22.40.

Shares of Theseus Pharmaceuticals stock traded down $0.44 on Wednesday, reaching $7.35. The stock had a trading volume of 207 shares, compared to its average volume of 67,757. The company has a 50 day moving average price of $11.11 and a 200 day moving average price of $12.18. Theseus Pharmaceuticals has a 1 year low of $7.21 and a 1 year high of $24.54.

Theseus Pharmaceuticals (NASDAQ:THRX – Get Rating) last released its earnings results on Thursday, March 10th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.01). As a group, equities research analysts forecast that Theseus Pharmaceuticals will post -1.17 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in THRX. Strs Ohio acquired a new stake in Theseus Pharmaceuticals during the 4th quarter valued at approximately $34,000. Northern Trust Corp acquired a new stake in Theseus Pharmaceuticals during the 4th quarter valued at approximately $1,229,000. Bank of America Corp DE acquired a new stake in Theseus Pharmaceuticals during the 4th quarter valued at approximately $100,000. TD Asset Management Inc. acquired a new stake in Theseus Pharmaceuticals during the 4th quarter valued at approximately $713,000. Finally, Citigroup Inc. acquired a new stake in Theseus Pharmaceuticals during the 4th quarter valued at approximately $40,000. Institutional investors and hedge funds own 90.00% of the company’s stock.

About Theseus Pharmaceuticals (Get Rating)

Theseus Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial.

Further Reading